Positives

• Patients who started molnupiravir within 5 days of infection commonly report fewer lingering symptoms at six months CIDRAP.
• Molnupiravir was linked to lower rates of fatigue, malaise, abnormal heart rhythm, pulmonary embolism, and cognitive impairment in the same dataset New England Journal of Medicine.
• Patients describe molnupiravir as a five-day oral course they could start at home without infusion logistics Yale Medicine.

Negatives

• Effect sizes on PASC reduction are modest, and most clinical guidelines reserve molnupiravir as a second-line antiviral when nirmatrelvir/ritonavir (Paxlovid) is contraindicated NIH.
  
  

Hurdles & Side Effects

• Adverse events were not significantly different from placebo in trials, but the FDA emergency-use authorization narrowed eligibility to high-risk patients only, limiting access for younger or otherwise-healthy Long COVID-prevention candidates PMC.